[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100531233":3},{"organization":4,"armGroups":7,"interventions":14,"overallOfficials":10,"centralContacts":22,"locations":28,"responsibleParty":41,"collaborators":10,"id":43,"slug":44,"hasResults":45,"nctId":46,"briefTitle":47,"officialTitle":48,"acronym":10,"eligibilityCriteria":49,"healthyVolunteers":45,"sex":50,"minAge":51,"maxAge":52,"enrollmentInfo":53,"targetDuration":10,"studyType":56,"phases":10,"briefSummary":57,"conditions":58,"keywords":10,"overallStatus":63,"whyStopped":10,"lastUpdateSubmitDate":64,"lastUpdatePostDateStruct":65,"startDateStruct":68,"completionDateStruct":70,"leadSponsor":72,"locationsCount":73},{"fullName":5,"class":6},"Fujian Cancer Hospital","OTHER_GOV",[8],{"label":9,"type":10,"description":11,"interventionNames":12},"cervical cancer patients with radiotherapy",null,"Radiotherapy is the main treatment strategy with an overall dose of over 75Gy.",[13],"Radiation: Treatment mainly composed of external pelvic beam radiotherapy (EBRT) followed by individualized high-dose-rate intracavitary brachytherapy (HDR-ICBT) .",[15],{"type":16,"name":17,"description":18,"armGroupLabels":19,"otherNames":20},"RADIATION","Treatment mainly composed of external pelvic beam radiotherapy (EBRT) followed by individualized high-dose-rate intracavitary brachytherapy (HDR-ICBT) .","The chemotherapy regimens included cisplatin (40 mg\u002Fm2) or nedaplatin (80 mg\u002Fm2) monotherapy or combined with paclitaxel (135 mg\u002Fm2) every three weeks during radiotherapy.",[9],[21],"concurrent chemothearpy",[23],{"name":24,"role":25,"phone":26,"phoneExt":10,"email":27},"Yang Sun","CONTACT","+8615959028989","sunyang@fjzlhospital.com",[29],{"facility":5,"status":10,"city":30,"state":31,"zip":32,"country":33,"countryCode":34,"cosmosGeoPoint":35,"geoPoint":40,"contacts":10},"Fuzhou","Fujian","350014","China","CN",{"type":36,"coordinates":37},"Point",[38,39],119.30611,26.06139,{"lat":39,"lon":38},{"type":42,"investigatorFullName":10,"investigatorTitle":10,"investigatorAffiliation":10,"oldNameTitle":10,"oldOrganization":10},"SPONSOR","100531233","mri-based-signatures-for-survival-prediction-in-cervical-cancer-with-radiotherapy-100531233",false,"NCT06197126","MRI-based Signatures for Survival Prediction in Cervical Cancer With Radiotherapy","A Prognostic Model Based on MRI for Cervical Cancer Patients Treated With Radiotherapy","Inclusion Criteria:\n\n* (1) pathologically confirmed CC, (2) initially treated in our center\n\nExclusion Criteria:\n\n* (1) lack of pre-treatment MRI, (2) prior anti-tumor treatment, (3) pelvic surgery history, (4) incomplete therapy, (5) loss of follow-up","FEMALE","20 Years","85 Years",{"count":54,"type":55},200,"ESTIMATED","OBSERVATIONAL","This study aims to validate the value of tumor involvement features based on MRI in cervical cancer, facilitate the development of a more appropriate model for risk stratification, and help patients with varying risk profiles make appropriate decisions in treatment selection and follow-up plans.",[59,60,61,62],"Cervical Cancer","Radiotherapy","Prognostic Model","MRI","NOT_YET_RECRUITING","2023-12-25",{"date":66,"type":67},"2024-01-09","ACTUAL",{"date":69,"type":55},"2024-01-01",{"date":71,"type":55},"2028-12-31",{"name":5,"class":6},1]